Transgenomic buys Clinical Data markers

Transgenomic has struck a deal to buy Clinical Data's genetic tests for heart disease along with the biomarkers needed for the PGxPredict tests for $15.4 million. The deal provides $6 million upfront with the rest in one-year and three-year promissory notes. Report

Suggested Articles

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.

Illumina will drop $8 billion to reacquire its former spinout, which after nearly five years is nearing completion of its cancer-seeking blood test.

The CE Mark for the system’s fourth iteration follows a July 2019 approval from the FDA.